AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05048186 — intervention group
Intervention type: BEHAVIORAL
Intervention: Attention Deficit Hyperactivity Disorder Treatment Decision Aid
Description: The parent pre-visit cards from the Cincinnati Children's Hospital's Attention Deficit Hyperactivity Disorder (ADHD) Treatment for School Age Children Decision Aid were used in this study. The 6 pre-visit cards provide an overview of ADHD treatment options, the respective benefits and downsides of each option, and questions to elicit goals/preferences. The four different treatment options presented were: (1) watchful waiting, (2) behavioral treatment, (3) medication treatment, and (4) combined treatment (behavioral and medication together).
Study NCT05273814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab intravenous infusion 200mg d4
Study NCT06119568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot assisted laparoscopic Radical/simple nephrectomy (RN), Partial nephrectomy (PN) or Radical Prostatectomy (RP).
Description: Three different surgery interventions: 1. Radical Nephrectomy: Complete remove of the kidney; 2. Partial Nephrectomy: Partial remove of a section in the kidney. 3. Radical Prostatectomy: Complete remote of the prostate gland. During each of these procedures removal of regional lymph nodes (lymphadenectomy) and lysis of abdominal lesions may be performed according to patient medical condition and/or surgeon criteria.
Study NCT05273814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed intravenous infusion 500mg/m2 d1
Study NCT05273814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Pemetrexed intravenous infusion 7.5mg/kg，d1
Study NCT05681234 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-RD2
Description: Patients will receive 5-10 mCi 18F-RD2
Study NCT04783025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended Gaming COVID-19 Training System (BGCTS)
Description: BGCTS is a blended training programme integrated with games and short video clips for Residential Care Home staffs to learn the principles of infection control and reinforce actions needed to stop the spread of COVID-19 within the RCHs, and to care for those residents suspected of having COVID-19. The contents of the training will refer to the evidence-based contents from The COVID-19 Risk Communication Package For Healthcare Facilities.~Dosage of the intervention. Staffs are encouraged to learn each topic independently in 15 minutes. It will take a total of 120 minutes to complete all eight topics in 2 weeks. Staffs will attend two 30-minute face-to-face group sessions conducted by research nurse (and the Infection Control Officer of the RCH) to clarify concepts (one per week; after playing the games). Scores and progress bar will be shown to the staff so as a form of motivation to encourage continuous participation in the training.
Study NCT04783025 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care, infection control briefing
Description: Participants in the CG will receive usual care, the infection control briefing given by the Infection Control Officer (ICO) of the RCHs to all staffs. Usually the briefing is irregular, non-standardized and determined by ICOs, depending on when the ICOs receive the information about infection control practice from Centre for Health Protection of the Hong Kong government. The format and duration of this briefing is determined by the ICO. Some ICOs deliver the infection control information in the form of posters or a written document, and circulate these materials to all staffs.
Study NCT05695469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart resuscitation glove (ResuGlove)
Description: Participants will be randomly assigned into two equal groups using the online-based random number generator (https://www.random.org). Participants in the ResuGlove group will perform hand-only CPR wearing the ResuGlove with a running feedback program for 2 minutes.
Study NCT05695469 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smart resuscitation glove (ResuGlove)
Description: Participants will be randomly assigned into two equal groups using the online-based random number generator (https://www.random.org). Participants in the ResuGlove group will perform hand-only CPR wearing the ResuGlove with a running feedback program for 2 minutes.
Study NCT05695469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional CPR
Description: Participants in the traditional CPR group will perform hand-only CPR without the ResuGlove and feedback guidance for 2 minutes.
Study NCT05648006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OH2
Description: Oncolytic Type 2 Herpes Simplex Virus
Study NCT05648006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m2, orally administered twice a day, D1 to D14, repeated every 3 weeks
Study NCT05648006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2, orally administered twice a day, D1 to D14, repeated every 3 weeks
Study NCT05648006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab: 7.5 mg/kg, intravenously, once every 3 weeks.
Study NCT05695469 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional CPR
Description: Participants in the traditional CPR group will perform hand-only CPR without the ResuGlove and feedback guidance for 2 minutes.
Study NCT05395234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cook Like A Boss Online - virtual week long cooking camp
Description: The original Cook Like A Boss camp style intervention, was based on the Cook-Ed Model (Asher et al., 2020) and underpinned by SLT and ELT (Bandura \& McClelland, 1977; Kolb, 1984). The content was developed to ensure it was age-appropriate in line with the guidelines (Dean et al., 2021a) and included co-creation. The camp was designed to introduce the children to a range of food and skills and to nurture an initial interest in cooking. The adapted online version of the camp included five daily videos of the original chef performing the recipes. Minor adaptions included the removal of cooking pasta from scratch due to equipment concerns, reordering the days, and chef suggestions around alternative equipment/ingredients to use. The five daily videos were: 1) Introduction \& flatbreads; 2) Chicken Chowder; 3) Baking day; 4) Chilli non Carne; 5) Honey Chilli Chicken
Study NCT04986475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music therapy was performed by listening to the ney sound during the non-stress test procedure.
Study NCT06453252 — intervention group
Intervention type: OTHER
Intervention: we are aiming to develop a Scoring system based on certain variables derived from both groups
Description: We are aiming to develop a Scoring system based on certain variables derived from both group
Study NCT03468634 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: endoscopy
Description: Oesophageal endoscopy with biopsy
Study NCT05119790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] BIIB122 ([14C] DNL151)
Description: Oral dose
Study NCT05246644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: we will use IV acetaminophen and an oral placebo or IV placebo and active oral acetaminophen
Study NCT05246644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen
Description: we will use IV acetaminophen and an oral placebo or IV placebo and active oral acetaminophen
Study NCT06408987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopically assisted
Description: Arthroscopically-Assisted reduction through anterolateral portal for visualization and other accessory portals for instrumentation to achieve reduction and postoperative immobilization in a hip spica.
Study NCT06408987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open surgical reduction
Description: Open reduction through a bikini incision anterior approach and postoperative immobilization in a hip spica.
Study NCT04837690 — intervention group
Intervention type: PROCEDURE
Intervention: UEMR
Description: (1) the colorectal lumen was completed deflated with 500-1000 mL sterile water using a flushing pump; (2) the lesion and 2-3 mm of normal mucosa surrounding the base of the polyp were snared and subsequently resected with an electrosurgical generator
Study NCT05157971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT05157971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given SC, IV or IT
Study NCT05157971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT05157971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study NCT05157971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT
Study NCT05157971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IM or IV
Study NCT05157971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT05157971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT05157971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT04535817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab Injection [Xolair]
Description: 300mg via 2 subcutaneous injections every 4 weeks
Study NCT05030610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BeatIt-ASD
Description: BeatIt-ASD, designed to be implemented with autistic individuals, is an adaptation of BeatIt. The intervention aims to improve mood and decrease depressive symptoms through an increase in meaningful engagement in recreational, domestic, and social/leisure activities.
Study NCT06320106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality baseline assessment
Description: They undergo a baseline assessment (including cognitive level and pen and paper tests for visuo-spatial abilities). Then they perform a spatial navigation assessment with an immersive virtual reality application delivered by the Oculus Quest viewer. The spatial navigation application consists of a 5-way star-maze adapted from (Biffi et al 2020 Front. Psychol.) where the participants have to find a treasure hidden at the end of one way. The application measures both the learning of spatial information and the strategy used (egocentric or allocentric).~After the session, the participants fill questionnaires related to cyber-sickness and usability of the application.
Study NCT05308407 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Focus Groups
Description: No intervention involved in this phase of the study
Study NCT05308407 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pilot randomized controlled trial
Description: The intervention is a virtually delivered, 12 weekly group-based active video game-centered lifestyle physical activity intervention (POWER UP) targeting affect to improve function and quality of life in insufficiently active AYAs with central nervous system tumors.
Study NCT04963036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Entropy and NOL-Guided Goal Directed Anesthesia
Description: Entropy-guided Anesthesia (Propofol infusion in order to maintain Entropy between 45 and 55) and NOL-guided Analgesia (Remifentanil infusion in order to maintain NOL-Index between 10 and 25).
Study NCT04963036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Group (Entropy and blinded NOL)
Description: Entropy-guided Anesthesia (Propofol infusion in order to obtain Entropy between 45 and 55) and Remifentanil infusion at the discretion of the anesthetist in charge, based on current practice: patient vitals (Heart Rate, Blood Pressure, Respiratory Rate...), movements, spontaneous breathing, experience....~In this group, nociception monitor screen will be concealed and the NOL index will not be available for guidance of remifentanil dosing).
Study NCT06173544 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Participants randomized to this arm will received enhanced standard of care.
Study NCT06173544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Friendship Bench (AFB)
Description: Participants randomized to this arm will receive the Adapted Friendship Bench protocol delivered by a trained counselor.
Study NCT06173544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Friendship Bench (EFB)
Description: Participants randomized to this arm will receive the Enhanced Friendship Bench protocol delivered by a trained counselor and a peer supporter.
Study NCT05051670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: da vinc SP gastrectomy
Description: radical subtotal gastrectomy performed by da vinci SP
Study NCT04952597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle
Study NCT04952597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle
Study NCT04952597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent Chemoradiotherapy
Description: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.~Etoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles~Thoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)
Study NCT06106100 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antireflux mucosal ablation
Description: Patients are instructed to fast for 6 hours pre-procedurally, which are performed under intravenous propofol sedation. Retroflexion endoscopy to visualize the cardia is performed, followed by mucosa markings with straight-fire APC catheter (ERBE Electromedizin, Tübingen, Germany) in forced coagulation mode (VIO300D, ERBE Electromedizin, Tübingen, Germany, 20W). The marking site at 1-cm and 2-cm distal to squamocolumnar junction at anterior-posterior and lesser curvature site, respectively, sparing the greater curvature site of cardia, is done. After marking, mucosal ablation (forced coagulation mode, 1L/min, 80W) is performed at marking site in a hoarse-shoe shape. Adequate ablation depth is defined as reaching the submucosal layer with blackish discolored tissue with carbonization
Study NCT06106100 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Patients are instructed to fast for 6 hours pre-procedurally, which are performed under intravenous propofol sedation. Retroflexion endoscopy to visualize the cardia is performed. Using the straight-fire APC catheter to touch the marking sites similar to the treatment group without electrocauterization is performed.
Study NCT06049498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mongolian Medicine ZhenBao Pills
Description: Mongolian Medicine ZhenBao Pills, orally, 15 pills each time, twice a day.
Study NCT06049498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mongolian Medicine ZhenBao Pills Placebo
Description: Mongolian Medicine ZhenBao Pills placebo, orally, 15 pills each time, twice a day.
Study NCT04745754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embedded primary care in cancer survivorship model
Description: Primacy care physicians will receive comprehensive training in cancer survivorship care for low-risk, early stage breast and colorectal patients. Training will include continuing medical education (CME) modules, webinars, and in-person discussion and clinical shadowing.
Study NCT05458492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus, tablets 2 mg/day with dose adjustment of 1 to 3 mg/day for residual concentrations between 4 and 10 ng/mL~1 dose daily for 16 weeks
Study NCT05563311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise on High-intensity interval training
Description: 3 times a week, for 8 weeks
Study NCT05614258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG206
Description: All participants in this study will receive the study drug ADG206 in one of the designed dosage level. ADG206 will be administered by intravenous infusion over 60-90 minutes on Day 1 of each treatment cycle until disease progression, intolerable toxicities or withdrawal of consent, or up to 2 years.
Study NCT06032104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dry beans
Description: 0.5 cup of Bush's Best Cannellini Beans, three times per day before meals blended into a smoothie. If interested and depending on tolerance, participants will also have the opportunity to gradually increase the bean smoothie to a maximum of 1 cup three times per day before meals during the last week of the two-week bean smoothie intervention. If patient cannot not tolerate 1.5 cup of canned cannellini bean, we will reduce per tolerance or offer the option of choosing a bean-based flour (100 gram/day, 23% fiber from Archer Daniels Midland)
Study NCT06032104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Usual diet
Description: Usual diet without adding the bean smoothie
Study NCT04707118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin+Nab-paclitaxel+GEM
Description: Laparoscopic exploration + thermal perfusion cisplatin 40 mg/m2, Postoperative exploration D1, 8 Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 after the second thermal perfusion 4 weeks plan, 6 cycles
Study NCT04707118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel+GEM
Description: Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 4 weeks plan, 6 cycles
Study NCT04314375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Budesonide
Description: 3 milligrams once daily for ages 5 to 11 years 11 months. 6 milligrams once daily for ages 12 to 17 years.
Study NCT04314375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Budesonide
Description: 6 milligrams once daily for ages 5 to 11 years 11 months. 9 milligrams once daily for ages 12 to 17 years.
Study NCT04314375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo once daily.
Study NCT06652750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Management
Description: Conducting routine in-office follow-up for CIED paitents
Study NCT06652750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5G Cloud Follow-up
Description: This study employed a 5G-cloud follow-up platform, a research tool that allows a device specialist to test, and program CIEDs in real-time from a remote location via an internet connection or mobile wireless network. Consistent with of the 5G remote support terminal externally connected to the programmer, a PAD was installed with a 5G-cloud follow-up app. The onsite medical staff began the cloud follow-up session by contacting the remote device specialist via video call. The connection to the CIED was made by the medical staff through the use of a standard programmer. He was in charge of turning on the programmer and applying the programmer wand to the patient's device. After an initial introduction, communication was established and continued via the wand connection. The remote device specialist logged into the 5G-cloud follow-up app with two-step verification. The remote device specialist then had complete control of the programmer to check and reprogram the device as needed.
Study NCT05847387 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: V-Check
Description: Preoperative analysis of endothelial tissue staining with vital dye (Trypan Blue 0.05%) and image analysis to identify the percentage of Trypan Blue Positive Areas, corresponding to dead endothelial cells and/or denuded areas of endothelium, in tissues destined to keratoplasty
Study NCT06106685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose washed microbiota suspension
Description: The high-dose group will be administered a high dose of washed microbiota suspension。
Study NCT06106685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose washed microbiota suspension
Description: The low-dose group will be administered a low dose of washed microbiota suspension.
Study NCT06239454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: interleaving stimulation
Description: ILS consists of two rapid and alternate stimulation programs with different contacts, amplitudes, and pulse width but the same frequency up to a maximum of 125Hz. Contact selection is determined by postoperative stereotactic computed tomography and clinical evaluation to achieve a balance between motor improvement and tolerable side effects. For example, ILS is successfully applied for PD motor symptoms (stimulation of subthalamic nucleus) as well as dyskinesia (additional stimulation of zona incerta).
Study NCT06239454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: empirical stimulation
Description: Patients are settled with simple polar stimulation with combined parameters adjustment (monopolar mode, 60\~90µs pulse width, 130\~185Hz frequency and varied voltage) during the follow-up.